HistoScanning(TM) is a novel ultrasonography technique for visualization of prostate cancer.
The technology it uses and its encouraging results in prostate cancer foci detection in 29 men with prostate cancer have been described previously. A recent study confirmed these results in 31 patients. The sensitivity and specificity of prostate cancer foci detection were 90% and 72%, respectively. These promising results raised the question of whether HistoScanning(TM) technology might also be helpful in therapy planning. Preoperative knowledge of the distribution and size of tumours might be useful for treatment planning of a nerve-sparing radical prostatectomy. We tested the ability of HistoScanning(TM) to predict a negative surgical margin in 80 patients undergoing radical prostatectomy.
OBJECTIVE:To assess the accuracy of HistoScanning(TM) (HS) as a visualization tool for preoperative treatment planning for nerve-sparing (NS) radical prostatectomy (RP).
PATIENTS AND METHODS:A retrospective study was carried out on 80 patients with prostate cancer undergoing RP from October 2009 to December 2009. All patients underwent a HS procedure 1 day before surgery. Frozen sections (FSs) were performed on each latero-posterior side of the prostate to assess for the presence of cancer. On the HS analysis, the region corresponding to that removed at FS was assessed for suspicious lesions. The size of suspicious lesions within this volume was compared with the FS histopathological analysis.
RESULTS:HS results corresponded to a 93% probability of having a negative surgical margin in the FSs. The presence of a HS volume ≥0.2 mL in a specific side was associated with a 3.7 times increased risk of a positive surgical margin at FS.
CONCLUSIONS: HS has the potential to assist in the planning of NSRP. Larger, multicentre studies need to be performed for validation of these encouraging results.
Written by:
Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T. Are you the author?
Martini-Clinic, Prostate Cancer Center Department of Urology, University Medical Center Eppendorf, Hamburg, Germany; International Prevention Research Institute (iPRI), Lyon, France; University College London and University College London Hospitals Trust, London, UK; Urological Clinic, Munich; Planegg Department of Pathology, University Medical Center Eppendorf, Hamburg, Germany.
Reference: BJU Int. 2012 Aug 9. Epub ahead of print.
doi: 10.1111/j.1464-410X.2012.11396.x
PubMed Abstract
PMID: 22882794
UroToday.com Prostate Cancer Section
